Evidence map›Paper›PMID 30406165›Full record

ArticleData in brief2018

Spherical particles derived from TMV virions enhance the protective properties of the rabies vaccine.

N A Nikitin, I N Matveeva, E A Trifonova, N M Puhova, A Ya Samuylenko, S A Gryn, J G Atabekov, O V Karpova

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Data in brief, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Plant Viruses: New Opportunities under the Pandemic.Herald of the Russian Academy of Sciences · 2022
    Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

N A NikitinDepartment of Virology, Lomonosov Moscow State University, 1/12 Leninskie gory, Moscow 119234, Russia.
I N MatveevaAll-Russian Scientific Research and Technological Institute of Biological Industry, VNITIBP 17, Moscow region, Shchelkovsky district 141142, Russia.
E A TrifonovaDepartment of Virology, Lomonosov Moscow State University, 1/12 Leninskie gory, Moscow 119234, Russia.
N M PuhovaAll-Russian Scientific Research and Technological Institute of Biological Industry, VNITIBP 17, Moscow region, Shchelkovsky district 141142, Russia.
A Ya SamuylenkoAll-Russian Scientific Research and Technological Institute of Biological Industry, VNITIBP 17, Moscow region, Shchelkovsky district 141142, Russia.
S A GrynAll-Russian Scientific Research and Technological Institute of Biological Industry, VNITIBP 17, Moscow region, Shchelkovsky district 141142, Russia.
J G AtabekovDepartment of Virology, Lomonosov Moscow State University, 1/12 Leninskie gory, Moscow 119234, Russia.
O V KarpovaDepartment of Virology, Lomonosov Moscow State University, 1/12 Leninskie gory, Moscow 119234, Russia.
Lomonosov Moscow State University · RUResearch and Technological Institute of Biological Industry · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this study the ability of spherical particles (SPs) obtained from the tobacco mosaic virus (TMV) virions to enhance the immunogenic potential of the vaccine was evaluated. TMV SPs were shown to increase the protective properties of the widely used effective Russian adjuvant-free rabies vaccine, composed of killed rabies virions. The results of the NIH potency test showed enhancement of protectivity, that is comparable with the effect of the incomplete Freund׳s adjuvant on the same vaccine.

Indexed as

AdjuvantPlant virusRabies vaccineSpherical particles

Identifiers

PMID30406165
PMCPMC6214837
OpenAlexW2895861461

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.